Co-targeting PLK1 and mTOR induces synergistic inhibitory effects against esophageal squamous cell carcinoma

Plumbagin inhibits the proliferation and survival of esophageal cancer cells by blocking STAT3-PLK1-AKT signaling

(2018) Ying-Ya Cao et al.   Cell Death & Disease

Cancer statistics in China, 2015

(2016) Wanqing Chen et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Cancer statistics, 2016

(2016) Rebecca L. Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Recent Advances From Basic and Clinical Studies of Esophageal Squamous Cell Carcinoma

(2015) Shinya Ohashi et al.   GASTROENTEROLOGY

Targeting Polo-Like Kinases: A Promising Therapeutic Approach for Cancer Treatment

(2015) Xiaoqi Liu   Translational Oncology

Recent Advances and New Strategies in Targeting Plk1 for Anticancer Therapy

(2015) Kyung S. Lee et al.   TRENDS IN PHARMACOLOGICAL SCIENCES

What is synergy? The Saariselkä agreement revisited

(2015) Jing Tang et al.   Frontiers in Pharmacology

Therapeutic targeting of the mTOR-signalling pathway in cancer: benefits and limitations

(2014) M Moschetta et al.   BRITISH JOURNAL OF PHARMACOLOGY

Loss-of-function RNAi screens in breast cancer cells identify AURKB, PLK1, PIK3R1, MAPK12, PRKD2, and PTK6 as sensitizing targets of rapamycin activity

(2014) Oliver Ou et al.   CANCER LETTERS

Plk1 Phosphorylation of PTEN Causes a Tumor-Promoting Metabolic State

(2014) Z. Li et al.   MOLECULAR AND CELLULAR BIOLOGY

Growing knowledge of the mTOR signaling network

(2014) Kezhen Huang et al.   SEMINARS IN CELL & DEVELOPMENTAL BIOLOGY

Current clinical trials with polo-like kinase 1 inhibitors in solid tumors

(2013) Hyungshin Yim   ANTI-CANCER DRUGS

An open-label, single-arm, phase 2 trial of the polo-like kinase inhibitor volasertib (BI 6727) in patients with locally advanced or metastatic urothelial cancer

(2013) Walter M. Stadler et al.   CANCER

PDK1 Signaling Toward PLK1-MYC Activation Confers Oncogenic Transformation, Tumor-Initiating Cell Activation, and Resistance to mTOR-Targeted Therapy

(2013) J. Tan et al.   Cancer Discovery

mTOR Signaling in Growth Control and Disease

(2012) Mathieu Laplante et al.   CELL

4E-BP1 participates in maintaining spindle integrity and genomic stability via interacting with PLK1

(2012) Zeng-Fu Shang et al.   CELL CYCLE

Clinicopathologic significance and function of mammalian target of rapamycin activation in esophageal squamous cell carcinoma

(2012) Seok-Hyung Kim et al.   HUMAN PATHOLOGY

Rapamycin-Induced Insulin Resistance Is Mediated by mTORC2 Loss and Uncoupled from Longevity

(2012) D. W. Lamming et al.   SCIENCE

mTOR complex 2 signaling and functions

(2011) Won Jun Oh et al.   CELL CYCLE

Current and future directions in mammalian target of rapamycin inhibitors development

(2011) Angelica Fasolo et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Reciprocal Activation Between PLK1 and Stat3 Contributes to Survival and Proliferation of Esophageal Cancer Cells

(2011) Yu Zhang et al.   GASTROENTEROLOGY

Combination of Chemical Genetics and Phosphoproteomics for Kinase Signaling Analysis Enables Confident Identification of Cellular Downstream Targets

(2011) Felix S. Oppermann et al.   MOLECULAR & CELLULAR PROTEOMICS

Phosphorylated mTOR Expression is Associated with Poor Prognosis for Patients with Esophageal Squamous Cell Carcinoma

(2010) Kotaro Hirashima et al.   ANNALS OF SURGICAL ONCOLOGY

4E-BP1 Is a Key Effector of the Oncogenic Activation of the AKT and ERK Signaling Pathways that Integrates Their Function in Tumors

(2010) Qing-Bai She et al.   CANCER CELL

A functional link between Polo-like kinase 1 and the mammalian Target-Of-Rapamycin pathway?

(2010) Annelies G. Renner et al.   CELL CYCLE

Multifaceted polo-like kinases: drug targets and antitargets for cancer therapy

(2010) Klaus Strebhardt   NATURE REVIEWS DRUG DISCOVERY

mTOR: from growth signal integration to cancer, diabetes and ageing

(2010) Roberto Zoncu et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY

BI 6727, A Polo-like Kinase Inhibitor with Improved Pharmacokinetic Profile and Broad Antitumor Activity

(2009) D. Rudolph et al.   CLINICAL CANCER RESEARCH

Polo-like kinase inhibitors: an emerging opportunity for cancer therapeutics

(2009) Puneet Chopra et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Polo-Like Kinase (PLK) Inhibitors in Preclinical and Early Clinical Development in Oncology

(2009) P. Schoffski   ONCOLOGIST

Polo-like kinase 1 reaches beyond mitosis—cytokinesis, DNA damage response, and development

(2008) Tohru Takaki et al.   CURRENT OPINION IN CELL BIOLOGY

Polo on the Rise—from Mitotic Entry to Cytokinesis with Plk1

(2008) Mark Petronczki et al.   DEVELOPMENTAL CELL

Overexpression of PLK1 is associated with poor survival by inhibiting apoptosis via enhancement of survivin level in esophageal squamous cell carcinoma

(2008) Yan-Bin Feng et al.   INTERNATIONAL JOURNAL OF CANCER